DDX24

Across TCGA pan-cancer cohorts, DDX24 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DDX24 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DDX24 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DDX24 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, SCLC, and PRAD are the cancer types where DDX24 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.087	0.480	<.001	14	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
PRAD	DFS	Median	All	0.130	0.776	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.933	0.431	.012	10	view →
COAD	OS	Median	III,IV	0.168	0.691	.041	6	view →
SKCM	DFS	Median	II,III,IV	0.578	0.212	.021	6	view →
LUSC	DFS	Median	All	0.165	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DDX24–BLCA (DFS)

Open the BLCA breakdown →